<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00400153</url>
  </required_header>
  <id_info>
    <org_study_id>1012.56</org_study_id>
    <nct_id>NCT00400153</nct_id>
    <nct_alias>NCT00847652</nct_alias>
  </id_info>
  <brief_title>Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>Safety and Efficacy of Combivent Respimat in Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the effect of ipratropium
      bromide/salbutamol inhalation spray combination administered by the Respimat® inhaler (20
      mcg/100 mcg), ipratropium bromide inhalation spray administered by the Respimat® inhaler (20
      mcg), and COMBIVENT® MDI administered q.i.d on FEV1 at intervals over a treatment period of
      12 weeks in patients with COPD. Specifically, non-inferiority of Combivent Respimat® to
      COMBIVENT® MDI in FEV1 AUC from 0 to 6 hours , superiority of Combivent Respimat® to Atrovent
      Respimat® monotherapy in FEV1 AUC from 0 to 4 hours, and non-inferiority of Combivent
      Respimat® to Atrovent Respimat® monotherapy in FEV1 AUC from 4 to 6 hours will be analyzed.
      In addition, steady state pharmacokinetics over one dosing interval following 4 weeks of
      therapy will be characterized in a subgroup of patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 AUC0-6 at Day 85</measure>
    <time_frame>Before drug administration to 6 hours after drug administration on Day 85</time_frame>
    <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 85</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FEV1 AUC0-4 at Day 85</measure>
    <time_frame>Before drug administration to 4 hours after drug administration on Day 85</time_frame>
    <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 85</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FEV1 AUC4-6 at Day 85</measure>
    <time_frame>Between 4 hours and 6 hours after drug administration on Day 85</time_frame>
    <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 85</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC0-6 at Day 1</measure>
    <time_frame>Before drug administration to 6 hours after drug administration on Day 1</time_frame>
    <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC0-6 at Day 29</measure>
    <time_frame>Before drug administration to 6 hours after drug administration on Day 29</time_frame>
    <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC0-6 at Day 57</measure>
    <time_frame>Before drug administration to 6 hours after drug administration on Day 57</time_frame>
    <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 57</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC0-4 at Day 1</measure>
    <time_frame>Before drug administration to 4 hours after drug administration on Day 1</time_frame>
    <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC0-4 at Day 29</measure>
    <time_frame>Before drug administration to 4 hours after drug administration on Day 29</time_frame>
    <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC0-4 at Day 57</measure>
    <time_frame>Before drug administration to 4 hours after drug administration on Day 57</time_frame>
    <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 57</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC4-6 at Day 1</measure>
    <time_frame>Between 4 hours and 6 hours after drug administration on Day 1</time_frame>
    <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC4-6 at Day 29</measure>
    <time_frame>Between 4 hours and 6 hours after drug administration on Day 29</time_frame>
    <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC4-6 at Day 57</measure>
    <time_frame>Between 4 hours and 6 hours after drug administration on Day 57</time_frame>
    <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 57</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 Response at Day 1</measure>
    <time_frame>Within the first 2-hour post-treatment interval on Day 1</time_frame>
    <description>Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 Response at Day 29</measure>
    <time_frame>Within the first 2-hour post-treatment interval on Day 29</time_frame>
    <description>Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 Response at Day 57</measure>
    <time_frame>Within the first 2-hour post-treatment interval on Day 57</time_frame>
    <description>Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 57</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 Response at Day 85</measure>
    <time_frame>Within the first 2-hour post-treatment interval on Day 85</time_frame>
    <description>Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 85</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Therapeutic FEV1 Response at Day 1</measure>
    <time_frame>Within the first 2-hour post-treatment interval at Day 1</time_frame>
    <description>Achievement of recorded FEV1 measurement of at least 1.15 times of the corresponding test-day baseline value at any time during the first 2 hours of observation after drug administration at Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Therapeutic FEV1 Response at Day 29</measure>
    <time_frame>Within the first 2-hour post-treatment interval at Day 29</time_frame>
    <description>Achievement of recorded FEV1 measurement of at least 1.15 times of the corresponding test-day baseline value at any time during the first 2 hours of observation after drug administration at Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Therapeutic FEV1 Response at Day 57</measure>
    <time_frame>Within the first 2-hour post-treatment interval at Day 57</time_frame>
    <description>Achievement of recorded FEV1 measurement of at least 1.15 times of the corresponding test-day baseline value at any time during the first 2 hours of observation after drug administration at Day 57</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Therapeutic FEV1 Response at Day 85</measure>
    <time_frame>Within the first 2-hour post-treatment interval at Day 85</time_frame>
    <description>Achievement of recorded FEV1 measurement of at least 1.15 times of the corresponding test-day baseline value at any time during the first 2 hours of observation after drug administration at Day 85</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Therapeutic FEV1 Response at Day 1</measure>
    <time_frame>During the 6-hour observation period after drug administration at Day 1</time_frame>
    <description>The time interval between the onset and the the termination of a therapeutic FEV1 response (at least 1.15 times the corresponding test-day baseline value) during the 6-hour observation period at Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Therapeutic FEV1 Response at Day 29</measure>
    <time_frame>During the 6-hour observation period after drug administration at Day 29</time_frame>
    <description>The time interval between the onset and the the termination of a therapeutic FEV1 response (at least 1.15 times the corresponding test-day baseline value) during the 6-hour observation period at Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Therapeutic FEV1 Response at Day 57</measure>
    <time_frame>During the 6-hour observation period after drug administration at Day 57</time_frame>
    <description>The time interval between the onset and the the termination of a therapeutic FEV1 response (at least 1.15 times the corresponding test-day baseline value) during the 6-hour observation period at Day 57</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Therapeutic FEV1 Response at Day 85</measure>
    <time_frame>During the 6-hour observation period after drug administration at Day 85</time_frame>
    <description>The time interval between the onset and the the termination of a therapeutic FEV1 response (at least 1.15 times the corresponding test-day baseline value) during the 6-hour observation period at Day 85</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Peak FEV1 Response at Day 1</measure>
    <time_frame>Within the 6-hour post-treatment observation period at Day 1</time_frame>
    <description>The first time point at which the maximum change in recorded FEV1 data from the corresponding test-day baseline occurred during the 6-hours observation period after drug administration at Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Peak FEV1 Response at Day 29</measure>
    <time_frame>Within the 6-hour post-treatment observation period at Day 29</time_frame>
    <description>The first time point at which the maximum change in recorded FEV1 data from the corresponding test-day baseline occurred during the 6-hours observation period after drug administration at Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Peak FEV1 Response at Day 57</measure>
    <time_frame>Within the 6-hour post-treatment observation period at Day 57</time_frame>
    <description>The first time point at which the maximum change in recorded FEV1 data from the corresponding test-day baseline occurred during the 6-hours observation period after drug administration at Day 57</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Peak FEV1 Response at Day 85</measure>
    <time_frame>Within the 6-hour post-treatment observation period at Day 85</time_frame>
    <description>The first time point at which the maximum change in recorded FEV1 data from the corresponding test-day baseline occurred during the 6-hours observation period after drug administration at Day 85</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC0-6 at Day 1</measure>
    <time_frame>Before drug administration to 6 hours after drug administration at Day 1</time_frame>
    <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC0-6 at Day 29</measure>
    <time_frame>Before drug administration to 6 hours after drug administration at Day 29</time_frame>
    <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC0-6 at Day 57</measure>
    <time_frame>Before drug administration to 6 hours after drug administration on Day 57</time_frame>
    <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 57</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC0-6 at Day 85</measure>
    <time_frame>Before drug administration to 6 hours after drug administration on Day 85</time_frame>
    <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 85</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC0-4 at Day 1</measure>
    <time_frame>Before drug administration to 4 hours after drug administration on Day 1</time_frame>
    <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC0-4 at Day 29</measure>
    <time_frame>Before drug administration to 4 hours after drug administration on Day 29</time_frame>
    <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC0-4 at Day 57</measure>
    <time_frame>Before drug administration to 4 hours after drug administration on Day 57</time_frame>
    <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 57</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC0-4 at Day 85</measure>
    <time_frame>Before drug administration to 4 hours after drug administration on Day 85</time_frame>
    <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 85</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC4-6 at Day 1</measure>
    <time_frame>Between 4 hours and 6 hours after drug administration on Day 1</time_frame>
    <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC4-6 at Day 29</measure>
    <time_frame>Between 4 hours and 6 hours after drug administration on Day 29</time_frame>
    <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC4-6 at Day 57</measure>
    <time_frame>Between 4 hours and 6 hours after drug administration on Day 57</time_frame>
    <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 57</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC4-6 at Day 85</measure>
    <time_frame>Between 4 hours and 6 hours after drug administration on Day 85</time_frame>
    <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 85</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FVC Response at Day 1</measure>
    <time_frame>Within the first 2-hour post-treatment interval at Day 1</time_frame>
    <description>Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FVC Response at Day 29</measure>
    <time_frame>Within the first 2-hour post-treatment interval at Day 29</time_frame>
    <description>Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FVC Response at Day 57</measure>
    <time_frame>Within the first 2-hour post-treatment interval at Day 57</time_frame>
    <description>Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 57</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FVC Response at Day 85</measure>
    <time_frame>Within the first 2-hour post-treatment interval at Day 85</time_frame>
    <description>Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 85</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Medication Use on Pulmonary Test Day 1</measure>
    <time_frame>During the 6-hour pulmonary function testing after drug administration on Day 1</time_frame>
    <description>Number of patients used rescue medication during the 6-hour pulmonary function testing after drug administration on Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Medication Use on Pulmonary Test Day 29</measure>
    <time_frame>During the 6-hour pulmonary function testing after drug administration on Day 29</time_frame>
    <description>Number of patients used rescue medication during the 6-hour pulmonary function testing after drug administration on Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Medication Use on Pulmonary Test Day 57</measure>
    <time_frame>During the 6-hour pulmonary function testing after drug administration on Day 57</time_frame>
    <description>Number of patients used rescue medication during the 6-hour pulmonary function testing after drug administration on Day 57</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Medication Use on Pulmonary Test Day 85</measure>
    <time_frame>During the 6-hour pulmonary function testing after drug administration on Day 85</time_frame>
    <description>Number of patients used rescue medication during the 6-hour pulmonary function testing after drug administration on Day 85</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Night-time Rescue Medication Use</measure>
    <time_frame>During the 2-week baseline washout period and the 12-week treatment period</time_frame>
    <description>The mean number of puffs of rescue medication used during the night-time per week during the entire study (including baseline and on-treatment period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daytime Rescue Medication Use</measure>
    <time_frame>During the 2-week baseline washout period and the 12-week treatment period</time_frame>
    <description>The mean number of puffs of rescue medication used during the daytime per week during the entire study (including baseline and on-treatment period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Night-time Symptom Score</measure>
    <time_frame>During the 2-week baseline washout period and the 12-week treatment period</time_frame>
    <description>The weekly mean night-time symptom score per week during the entire study (including baseline and on-treatment period).
Night−time COPD symptoms: 0=none 1=some − slept well 2=woke once 3=woke several times 4=woke most of night</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daytime Symptom Score</measure>
    <time_frame>During the 2-week baseline washout period and the 12-week treatment period</time_frame>
    <description>The weekly mean daytime symptom score per week during the entire study (including baseline and on-treatment period).
Daytime COPD symptoms: 0=none 1=occasional 2=frequent, no interference with activities 3=most of day, interference with activities 4=prevent working and activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Peak Expiratory Flow Rate (PEFR)</measure>
    <time_frame>During the 2-week baseline washout period and the 12-week treatment period and PEFR taken before administration of study medication</time_frame>
    <description>The weekly mean trough PEFR during the entire study (including baseline and on-treatment period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Evaluation Score on Pulmonary Function Testing Day 29</measure>
    <time_frame>Prior to pulmonary function test on Day 29</time_frame>
    <description>Physician's Global Evaluation score is based on the need for concomitant medication, number and severity of exacerbations since the last visit, severity of cough, ability to exercise, amount of wheezing, etc.
Score: 1,2 = poor; 3,4 = fair; 5,6 =good; 7,8 = excellent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Evaluation Score on Pulmonary Function Testing Day 57</measure>
    <time_frame>Prior to pulmonary function test on Day 57</time_frame>
    <description>Physician's Global Evaluation score is based on the need for concomitant medication, number and severity of exacerbations since the last visit, severity of cough, ability to exercise, amount of wheezing, etc.
Score: 1,2 = poor; 3,4 = fair; 5,6 =good; 7,8 = excellent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Evaluation Score on Pulmonary Function Testing Day 85</measure>
    <time_frame>Prior to pulmonary function test on Day 85</time_frame>
    <description>Physician's Global Evaluation score is based on the need for concomitant medication, number and severity of exacerbations since the last visit, severity of cough, ability to exercise, amount of wheezing, etc.
Score: 1,2 = poor; 3,4 = fair; 5,6 =good; 7,8 = excellent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Chronic Obstructive Pulmonary Disease (COPD) Exacerbation During the On-treatment Period</measure>
    <time_frame>During the 12-week on-treatment period</time_frame>
    <description>COPD exacerbation is defined as an increase or new onset of more than one of the following respiratory symptoms (cough, sputum, sputum purulence, wheezing, dyspnea, and chest tightness) having a duration of three or more days requiring treatment with an antibiotic and/or systemic steroids with or without hospital admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD Exacerbation Rate During the On-treatment Period</measure>
    <time_frame>During the 12-week on-treatment period</time_frame>
    <description>Proportion of patients experiencing a COPD exacerbation per patient year. COPD exacerbation is defined as an increase or new onset of more than one of the following respiratory symptoms (cough, sputum, sputum purulence, wheezing, dyspnea, and chest tightness) having a duration of three or more days requiring treatment with an antibiotic and/or systemic steroids with or without hospital admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD Exacerbation During the On-treatment Period</measure>
    <time_frame>During the 12-week on-treatment period</time_frame>
    <description>COPD exacerbation is defined as an increase or new onset of more than one of the following respiratory symptoms (cough, sputum, sputum purulence, wheezing, dyspnea, and chest tightness) having a duration of three or more days requiring treatment with an antibiotic and/or systemic steroids with or without hospital admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency Distribution of Satisfaction Rating With Inhaler Attributes</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Rating Scores of Satisfaction With Inhaler - Overall Feeling of Inhaling Medicine</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Rating Scores of Satisfaction With Inhaler - Feeling That the Inhaled Dose Goes to the Lung</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Rating Scores of Satisfaction With Inhaler - Telling the Amount of Medication Left</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Rating Scores of Satisfaction With Inhaler - The Inhaler Works Reliably</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Rating Scores of Satisfaction With Inhaler - Ease of Inhaling a Dose From the Inhaler</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Rating Scores of Satisfaction With Inhaler - Instructions for Use</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Rating Scores of Satisfaction With Inhaler - The Inhaler is Durable</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Rating Scores of Satisfaction With Inhaler - Using the Inhaler</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Rating Scores of Satisfaction With Inhaler - Speed of Medicine Coming Out of the Inhaler</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Rating Scores of Satisfaction With Inhaler - Overall Satisfaction With Inhaler</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Preference (Respimat or MDI)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Frequency of patients due to device preference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rating of Action of Turning Clear Base of Respimat</measure>
    <time_frame>12 weeks</time_frame>
    <description>Frequency of patients due to rating of action of turning clear base of Respimat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Noncompartmental Pharmacokinetic Parameters of Ipratropium at Steady State</measure>
    <time_frame>Before drug administration to 6 hours after drug administration on Day 29</time_frame>
    <description>Geometric mean area under the plasma drug concentration time curve over one dosing interval (AUCτ). Each patient had eight plasma samples (trough pre-dose, 5, 15, 30, and 60 minutes post-dose, as well as 2, 4, and 6 hours post-dose).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Noncompartmental Parameters of Albuterol at Steady State</measure>
    <time_frame>Before drug administration to 6 hours after drug administration on Day 29</time_frame>
    <description>Geometric mean area under the plasma drug concentration time curve over one dosing interval (AUCτ). Each patient had eight plasma samples (trough pre-dose, 5, 15, 30, and 60 minutes post-dose, as well as 2, 4, and 6 hours post-dose).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Amounts of Ipratropium [μg] Excreted in Urine for 0-2 Hours</measure>
    <time_frame>Before drug administration to 2 hours after drug administration on Day 29</time_frame>
    <description>Cumulative amounts of Ipratropium [μg] excreted in urine - Planned time intervals 0-2, ss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Amounts of Albuterol [μg] Excreted in Urine for 0-2 Hours</measure>
    <time_frame>Before drug administration to 2 hours after drug administration on Day 29</time_frame>
    <description>Cumulative amounts of Albuterol [μg] excreted in urine - Planned time intervals 0−2,ss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Amounts of Ipratropium [μg] Excreted in Urine for 0-6 Hours</measure>
    <time_frame>Before drug administration to 6 hours after drug administration on Day 26</time_frame>
    <description>Cumulative amounts of Ipratropium [μg] excreted in urine - Planned time intervals 0−6,ss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Amounts of Albuterol [μg] Excreted in Urine for 0-6 Hours</measure>
    <time_frame>Before drug administration to 6 hours after drug administration on Day 29</time_frame>
    <description>Cumulative amounts of Albuterol [μg] excreted in urine - Planned time intervals 0−6, ss</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1480</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>COMBIVENT Respimat 20/100 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>COMBIVENT CFC-MDI 36/206 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ipratropium Respimat 20 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atrovent Respimat (20 mcg)</intervention_name>
    <arm_group_label>Ipratropium Respimat 20 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COMBIVENT MDI (36/206 mcg)</intervention_name>
    <arm_group_label>COMBIVENT CFC-MDI 36/206 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combivent Respimat (20 mcg/100 mcg)</intervention_name>
    <arm_group_label>COMBIVENT Respimat 20/100 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo via corresponding inhaler for blinding purposes</intervention_name>
    <arm_group_label>COMBIVENT Respimat 20/100 mcg</arm_group_label>
    <arm_group_label>COMBIVENT CFC-MDI 36/206 mcg</arm_group_label>
    <arm_group_label>Ipratropium Respimat 20 mcg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Outpatients of either sex, 40 years or older, with a diagnosis of COPD (FEV1 65% predicted
        normal and FEV1/FVC 70%).

        Exclusion Criteria:

        Patients with significant diseases other than COPD that may either put the patient at risk
        because of participation in the study or a disease which may influence the results of the
        study or the patient's ability to participate in the study, with a history of asthma or
        allergic rhinitis, who regularly use daytime oxygen therapy for more than 1 hour per day
        and in the investigator's opinion will be unable to abstain from the use of oxygen therapy
        or using oral corticosteroid me dication at unstable doses (i.e., less than 6 weeks on a
        stable dose) or at a dose in excess of the equivalent of 10 mg of prednisone per day or 20
        mg every other day will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1012.56.01006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01071 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01089 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sepulveda</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01045 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Torrence</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01050 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01062 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01088 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bay Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01065 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pensecola</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01048 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01093 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01077 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01083 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coeur D'Alene</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Olathe</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01056 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01066 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bowling Green</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01090 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01072 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01070 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01079 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01044 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01076 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01082 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01049 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01080 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01069 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Larchmont</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01068 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01078 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01067 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01060 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01087 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01057 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01081 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01085 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01084 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01073 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01075 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01047 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01059 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01063 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bellington</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01064 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.01074 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.54001 Centro Médico de la Dra. De Salvo</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.54002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.54003 Policlínica Bancaria</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.54004 Hospital Ramos Mejia</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.54010 Instituto Lanari</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.54011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.54015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.54005 Instituto de Diagnóstico Cardiovascular La Plata</name>
      <address>
        <city>La Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.54012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lanús</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.54009 Instituto de Investigaciones Clínicas</name>
      <address>
        <city>Mar del Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.54014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.54007 CLINICA PRIVADA de MONTE GRANDE</name>
      <address>
        <city>Monte Grande</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.54006 CENTRO PRIVADO de MEDICINA RESPIRATORIA</name>
      <address>
        <city>Paraná</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.54008 HOSPITAL ITALIANO de ROSARIO</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.54013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Miguel de Tucumán</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.3305A Centre hospitalier Germon &amp; Gauthier</name>
      <address>
        <city>Béthune</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.3303A Clinique de la Louvière</name>
      <address>
        <city>Lille Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.3301A Hôpital Ambroise Paré</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.3304A Centre Médical Erdre Saint Augustin</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.3302A Cabinet Médical</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.3302B Cabinet Médical</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.30001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.30011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.30013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.30009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heraklion</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.30007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Komotini</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.30010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Korinthos</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.30002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Larissa</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.30014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nafplio</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.30003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.82009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.82010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Geonggi-Do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.82008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gyeonggi-Do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.82001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.82002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.82005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.82006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.82007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.64004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dunedin</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.64001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grafton / Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.64003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.64006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tauranga</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.64005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wellington</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.48009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.48006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.48007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.48004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ostrow Wielkopolska</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.48005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.48002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Proszowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.48010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Radom</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.48001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.48011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.48003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.07010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.07001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.07002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.07003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.07005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.07007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.07008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.07009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St.Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.27002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bellville</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.27008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boksburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.27001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.27004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.27005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.27009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orange Grove</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.27003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paarl</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.27006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Park Town West</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.88604 Chang Gong Memorial Hospital</name>
      <address>
        <city>Keelong Town</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.88605 Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.88602 Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.88603 National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.88601 Chang Gung Memorial Hosp-Linkou</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.90001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.90005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Antalya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.90003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.90006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.90002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mersin</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.38005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dnyepropyetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.38006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.38001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.38002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.38004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.44009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ballieston, Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.44003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bury St Edmonds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.44002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.44006 Colchester General Hospital</name>
      <address>
        <city>Colchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.44007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Doncaster</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.44001 Medicine Evaluation Unit</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.44008 The Staploe Medical Centre</name>
      <address>
        <city>Soham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.44005 Morriston Hospital</name>
      <address>
        <city>Swansea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.56.44010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Windsor</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>France</country>
    <country>Greece</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
  </removed_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2006</study_first_submitted>
  <study_first_submitted_qc>November 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2006</study_first_posted>
  <results_first_submitted>April 3, 2009</results_first_submitted>
  <results_first_submitted_qc>April 3, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 1, 2009</results_first_posted>
  <last_update_submitted>June 9, 2014</last_update_submitted>
  <last_update_submitted_qc>June 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ipratropium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>COMBIVENT Respimat 20/100 mcg</title>
          <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
        </group>
        <group group_id="P2">
          <title>COMBIVENT CFC-MDI 36/206 mcg</title>
          <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
        </group>
        <group group_id="P3">
          <title>Ipratropium Respimat 20 mcg</title>
          <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="486"/>
                <participants group_id="P2" count="491"/>
                <participants group_id="P3" count="483"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="438"/>
                <participants group_id="P2" count="436"/>
                <participants group_id="P3" count="422"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="61"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>AE due to study disease worsening</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>AE due to other disease worsening</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>AE due to other condition</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons - not mentioned above</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The treated set (TS) included all randomized patients who were documented to have taken at least one actuation of the randomized treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>COMBIVENT Respimat 20/100 mcg</title>
          <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
        </group>
        <group group_id="B2">
          <title>COMBIVENT CFC-MDI 36/206 mcg</title>
          <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
        </group>
        <group group_id="B3">
          <title>Ipratropium Respimat 20 mcg</title>
          <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="486"/>
            <count group_id="B2" value="491"/>
            <count group_id="B3" value="483"/>
            <count group_id="B4" value="1460"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.8" spread="8.7"/>
                    <measurement group_id="B2" value="64.2" spread="9.2"/>
                    <measurement group_id="B3" value="64.3" spread="8.6"/>
                    <measurement group_id="B4" value="64.1" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="166"/>
                    <measurement group_id="B4" value="505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="316"/>
                    <measurement group_id="B2" value="322"/>
                    <measurement group_id="B3" value="317"/>
                    <measurement group_id="B4" value="955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="430"/>
                    <measurement group_id="B2" value="442"/>
                    <measurement group_id="B3" value="428"/>
                    <measurement group_id="B4" value="1300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168.8" spread="9.1"/>
                    <measurement group_id="B2" value="169.4" spread="9.4"/>
                    <measurement group_id="B3" value="168.8" spread="9.5"/>
                    <measurement group_id="B4" value="169.3" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.2" spread="20.0"/>
                    <measurement group_id="B2" value="77.8" spread="19.3"/>
                    <measurement group_id="B3" value="77.3" spread="21.0"/>
                    <measurement group_id="B4" value="77.8" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcoholic history</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Non drinker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="223"/>
                    <measurement group_id="B2" value="232"/>
                    <measurement group_id="B3" value="223"/>
                    <measurement group_id="B4" value="678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drinks - not interfere with participation in trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="263"/>
                    <measurement group_id="B2" value="258"/>
                    <measurement group_id="B3" value="260"/>
                    <measurement group_id="B4" value="781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drinks-poss. interfere with participation in trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking history</title>
          <units>pack years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.7" spread="27.7"/>
                    <measurement group_id="B2" value="52.4" spread="27.1"/>
                    <measurement group_id="B3" value="55.4" spread="27.6"/>
                    <measurement group_id="B4" value="53.2" spread="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>COPD duration</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.2" spread="6.1"/>
                    <measurement group_id="B2" value="8.6" spread="6.5"/>
                    <measurement group_id="B3" value="8.5" spread="6.4"/>
                    <measurement group_id="B4" value="8.4" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>FEV1 AUC0-6 at Day 85</title>
        <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 85</description>
        <time_frame>Before drug administration to 6 hours after drug administration on Day 85</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC0-6 at Day 85</title>
          <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 85</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.145" spread="0.007"/>
                    <measurement group_id="O2" value="0.149" spread="0.007"/>
                    <measurement group_id="O3" value="0.119" spread="0.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin is 0.05 liter</non_inferiority_desc>
            <p_value>0.7135</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0035</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0095</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.0222</ci_lower_limit>
            <ci_upper_limit>0.0152</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>FEV1 AUC0-4 at Day 85</title>
        <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 85</description>
        <time_frame>Before drug administration to 4 hours after drug administration on Day 85</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC0-4 at Day 85</title>
          <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 85</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.189" spread="0.007"/>
                    <measurement group_id="O2" value="0.190" spread="0.007"/>
                    <measurement group_id="O3" value="0.142" spread="0.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.047</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.028</ci_lower_limit>
            <ci_upper_limit>0.066</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>FEV1 AUC4-6 at Day 85</title>
        <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 85</description>
        <time_frame>Between 4 hours and 6 hours after drug administration on Day 85</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data 4-6 hours</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC4-6 at Day 85</title>
          <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 85</description>
          <population>Full Analysis Set for Pulmonary Function Test Data 4-6 hours</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="447"/>
                <count group_id="O2" value="449"/>
                <count group_id="O3" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.056" spread="0.008"/>
                    <measurement group_id="O2" value="0.066" spread="0.008"/>
                    <measurement group_id="O3" value="0.073" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin is 0.05 liters</non_inferiority_desc>
            <p_value>0.1389</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.017</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.011</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.039</ci_lower_limit>
            <ci_upper_limit>0.005</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC0-6 at Day 1</title>
        <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 1</description>
        <time_frame>Before drug administration to 6 hours after drug administration on Day 1</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC0-6 at Day 1</title>
          <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 1</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.173" spread="0.008"/>
                    <measurement group_id="O2" value="0.189" spread="0.008"/>
                    <measurement group_id="O3" value="0.124" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established for this comparison.</non_inferiority_desc>
            <p_value>0.124</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.016</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.010</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.036</ci_lower_limit>
            <ci_upper_limit>0.004</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC0-6 at Day 29</title>
        <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 29</description>
        <time_frame>Before drug administration to 6 hours after drug administration on Day 29</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC0-6 at Day 29</title>
          <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 29</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.154" spread="0.007"/>
                    <measurement group_id="O2" value="0.161" spread="0.007"/>
                    <measurement group_id="O3" value="0.127" spread="0.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established for this comparison.</non_inferiority_desc>
            <p_value>0.4888</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.007</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.026</ci_lower_limit>
            <ci_upper_limit>0.013</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC0-6 at Day 57</title>
        <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 57</description>
        <time_frame>Before drug administration to 6 hours after drug administration on Day 57</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC0-6 at Day 57</title>
          <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 57</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.146" spread="0.007"/>
                    <measurement group_id="O2" value="0.16" spread="0.007"/>
                    <measurement group_id="O3" value="0.118" spread="0.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established for this comparison.</non_inferiority_desc>
            <p_value>0.1433</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.014</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.033</ci_lower_limit>
            <ci_upper_limit>0.005</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC0-4 at Day 1</title>
        <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 1</description>
        <time_frame>Before drug administration to 4 hours after drug administration on Day 1</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC0-4 at Day 1</title>
          <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 1</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.211" spread="0.008"/>
                    <measurement group_id="O2" value="0.227" spread="0.008"/>
                    <measurement group_id="O3" value="0.149" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is purely exploratory.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.061</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.011</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>0.083</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC0-4 at Day 29</title>
        <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 29</description>
        <time_frame>Before drug administration to 4 hours after drug administration on Day 29</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC0-4 at Day 29</title>
          <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 29</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.197" spread="0.008"/>
                    <measurement group_id="O2" value="0.198" spread="0.008"/>
                    <measurement group_id="O3" value="0.153" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is purely exploratory.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.044</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.024</ci_lower_limit>
            <ci_upper_limit>0.065</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC0-4 at Day 57</title>
        <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 57</description>
        <time_frame>Before drug administration to 4 hours after drug administration on Day 57</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC0-4 at Day 57</title>
          <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 57</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.188" spread="0.007"/>
                    <measurement group_id="O2" value="0.200" spread="0.007"/>
                    <measurement group_id="O3" value="0.141" spread="0.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is purely exploratory.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.047</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.027</ci_lower_limit>
            <ci_upper_limit>0.067</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC4-6 at Day 1</title>
        <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 1</description>
        <time_frame>Between 4 hours and 6 hours after drug administration on Day 1</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data 4-6 hours</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC4-6 at Day 1</title>
          <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 1</description>
          <population>Full Analysis Set for Pulmonary Function Test Data 4-6 hours</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="447"/>
                <count group_id="O2" value="449"/>
                <count group_id="O3" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.008"/>
                    <measurement group_id="O2" value="0.115" spread="0.009"/>
                    <measurement group_id="O3" value="0.074" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established.</non_inferiority_desc>
            <p_value>0.0258</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.026</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.003</ci_lower_limit>
            <ci_upper_limit>0.049</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC4-6 at Day 29</title>
        <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 29</description>
        <time_frame>Between 4 hours and 6 hours after drug administration on Day 29</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data 4-6 hours</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC4-6 at Day 29</title>
          <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 29</description>
          <population>Full Analysis Set for Pulmonary Function Test Data 4-6 hours</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="447"/>
                <count group_id="O2" value="449"/>
                <count group_id="O3" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.068" spread="0.008"/>
                    <measurement group_id="O2" value="0.087" spread="0.008"/>
                    <measurement group_id="O3" value="0.078" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established.</non_inferiority_desc>
            <p_value>0.3749</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.011</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.032</ci_lower_limit>
            <ci_upper_limit>0.012</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC4-6 at Day 57</title>
        <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 57</description>
        <time_frame>Between 4 hours and 6 hours after drug administration on Day 57</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data 4-6 hours</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC4-6 at Day 57</title>
          <description>Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 57</description>
          <population>Full Analysis Set for Pulmonary Function Test Data 4-6 hours</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="447"/>
                <count group_id="O2" value="449"/>
                <count group_id="O3" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.063" spread="0.008"/>
                    <measurement group_id="O2" value="0.084" spread="0.008"/>
                    <measurement group_id="O3" value="0.073" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established.</non_inferiority_desc>
            <p_value>0.3355</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.011</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.011</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.033</ci_lower_limit>
            <ci_upper_limit>0.011</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 Response at Day 1</title>
        <description>Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 1</description>
        <time_frame>Within the first 2-hour post-treatment interval on Day 1</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 Response at Day 1</title>
          <description>Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 1</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.302" spread="0.008"/>
                    <measurement group_id="O2" value="0.323" spread="0.008"/>
                    <measurement group_id="O3" value="0.237" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established.</non_inferiority_desc>
            <p_value>0.0743</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.011</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.042</ci_lower_limit>
            <ci_upper_limit>0.002</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 Response at Day 29</title>
        <description>Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 29</description>
        <time_frame>Within the first 2-hour post-treatment interval on Day 29</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 Response at Day 29</title>
          <description>Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 29</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.302" spread="0.008"/>
                    <measurement group_id="O2" value="0.296" spread="0.008"/>
                    <measurement group_id="O3" value="0.237" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established.</non_inferiority_desc>
            <p_value>0.5711</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.006</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.011</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.015</ci_lower_limit>
            <ci_upper_limit>0.028</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 Response at Day 57</title>
        <description>Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 57</description>
        <time_frame>Within the first 2-hour post-treatment interval on Day 57</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 Response at Day 57</title>
          <description>Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 57</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.284" spread="0.008"/>
                    <measurement group_id="O2" value="0.296" spread="0.008"/>
                    <measurement group_id="O3" value="0.223" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established.</non_inferiority_desc>
            <p_value>0.2274</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.013</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.011</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.033</ci_lower_limit>
            <ci_upper_limit>0.008</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 Response at Day 85</title>
        <description>Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 85</description>
        <time_frame>Within the first 2-hour post-treatment interval on Day 85</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 Response at Day 85</title>
          <description>Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 85</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.293" spread="0.008"/>
                    <measurement group_id="O2" value="0.290" spread="0.008"/>
                    <measurement group_id="O3" value="0.225" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established.</non_inferiority_desc>
            <p_value>0.8065</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.003</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.011</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.018</ci_lower_limit>
            <ci_upper_limit>0.024</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 Response at Day 1</title>
        <description>Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 1</description>
        <time_frame>Within the first 2-hour post-treatment interval on Day 1</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 Response at Day 1</title>
          <description>Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 1</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.302" spread="0.008"/>
                    <measurement group_id="O2" value="0.323" spread="0.008"/>
                    <measurement group_id="O3" value="0.237" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is purely exploratory.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.065</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.011</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.043</ci_lower_limit>
            <ci_upper_limit>0.087</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 Response at Day 29</title>
        <description>Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 29</description>
        <time_frame>Within the first 2-hour post-treatment interval on Day 29</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 Response at Day 29</title>
          <description>Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 29</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.302" spread="0.008"/>
                    <measurement group_id="O2" value="0.296" spread="0.008"/>
                    <measurement group_id="O3" value="0.237" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is purely exploratory.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.065</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.011</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.044</ci_lower_limit>
            <ci_upper_limit>0.087</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 Response at Day 57</title>
        <description>Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 57</description>
        <time_frame>Within the first 2-hour post-treatment interval on Day 57</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 Response at Day 57</title>
          <description>Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 57</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.284" spread="0.008"/>
                    <measurement group_id="O2" value="0.296" spread="0.008"/>
                    <measurement group_id="O3" value="0.223" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is purely exploratory.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.011</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>0.081</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 Response at Day 85</title>
        <description>Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 85</description>
        <time_frame>Within the first 2-hour post-treatment interval on Day 85</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 Response at Day 85</title>
          <description>Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 85</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.293" spread="0.008"/>
                    <measurement group_id="O2" value="0.290" spread="0.008"/>
                    <measurement group_id="O3" value="0.225" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is purely exploratory.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.068</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.011</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.047</ci_lower_limit>
            <ci_upper_limit>0.089</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Therapeutic FEV1 Response at Day 1</title>
        <description>Achievement of recorded FEV1 measurement of at least 1.15 times of the corresponding test-day baseline value at any time during the first 2 hours of observation after drug administration at Day 1</description>
        <time_frame>Within the first 2-hour post-treatment interval at Day 1</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Therapeutic FEV1 Response at Day 1</title>
          <description>Achievement of recorded FEV1 measurement of at least 1.15 times of the corresponding test-day baseline value at any time during the first 2 hours of observation after drug administration at Day 1</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="8" upper_limit="59"/>
                    <measurement group_id="O2" value="12" lower_limit="7" upper_limit="48"/>
                    <measurement group_id="O3" value="28" lower_limit="11" upper_limit="361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Therapeutic FEV1 Response at Day 29</title>
        <description>Achievement of recorded FEV1 measurement of at least 1.15 times of the corresponding test-day baseline value at any time during the first 2 hours of observation after drug administration at Day 29</description>
        <time_frame>Within the first 2-hour post-treatment interval at Day 29</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Therapeutic FEV1 Response at Day 29</title>
          <description>Achievement of recorded FEV1 measurement of at least 1.15 times of the corresponding test-day baseline value at any time during the first 2 hours of observation after drug administration at Day 29</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="7" upper_limit="53"/>
                    <measurement group_id="O2" value="13" lower_limit="8" upper_limit="55"/>
                    <measurement group_id="O3" value="27" lower_limit="11" upper_limit="361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Therapeutic FEV1 Response at Day 57</title>
        <description>Achievement of recorded FEV1 measurement of at least 1.15 times of the corresponding test-day baseline value at any time during the first 2 hours of observation after drug administration at Day 57</description>
        <time_frame>Within the first 2-hour post-treatment interval at Day 57</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Therapeutic FEV1 Response at Day 57</title>
          <description>Achievement of recorded FEV1 measurement of at least 1.15 times of the corresponding test-day baseline value at any time during the first 2 hours of observation after drug administration at Day 57</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="8" upper_limit="361"/>
                    <measurement group_id="O2" value="12" lower_limit="7" upper_limit="59"/>
                    <measurement group_id="O3" value="29" lower_limit="11" upper_limit="361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Therapeutic FEV1 Response at Day 85</title>
        <description>Achievement of recorded FEV1 measurement of at least 1.15 times of the corresponding test-day baseline value at any time during the first 2 hours of observation after drug administration at Day 85</description>
        <time_frame>Within the first 2-hour post-treatment interval at Day 85</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Therapeutic FEV1 Response at Day 85</title>
          <description>Achievement of recorded FEV1 measurement of at least 1.15 times of the corresponding test-day baseline value at any time during the first 2 hours of observation after drug administration at Day 85</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="8" upper_limit="102"/>
                    <measurement group_id="O2" value="13" lower_limit="8" upper_limit="361"/>
                    <measurement group_id="O3" value="27" lower_limit="11" upper_limit="361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Therapeutic FEV1 Response at Day 1</title>
        <description>The time interval between the onset and the the termination of a therapeutic FEV1 response (at least 1.15 times the corresponding test-day baseline value) during the 6-hour observation period at Day 1</description>
        <time_frame>During the 6-hour observation period after drug administration at Day 1</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Therapeutic FEV1 Response at Day 1</title>
          <description>The time interval between the onset and the the termination of a therapeutic FEV1 response (at least 1.15 times the corresponding test-day baseline value) during the 6-hour observation period at Day 1</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189" lower_limit="29" upper_limit="323"/>
                    <measurement group_id="O2" value="219" lower_limit="42" upper_limit="336"/>
                    <measurement group_id="O3" value="104" lower_limit="0" upper_limit="309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Therapeutic FEV1 Response at Day 29</title>
        <description>The time interval between the onset and the the termination of a therapeutic FEV1 response (at least 1.15 times the corresponding test-day baseline value) during the 6-hour observation period at Day 29</description>
        <time_frame>During the 6-hour observation period after drug administration at Day 29</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Therapeutic FEV1 Response at Day 29</title>
          <description>The time interval between the onset and the the termination of a therapeutic FEV1 response (at least 1.15 times the corresponding test-day baseline value) during the 6-hour observation period at Day 29</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170" lower_limit="16" upper_limit="298"/>
                    <measurement group_id="O2" value="178" lower_limit="11" upper_limit="306"/>
                    <measurement group_id="O3" value="122" lower_limit="0" upper_limit="312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Therapeutic FEV1 Response at Day 57</title>
        <description>The time interval between the onset and the the termination of a therapeutic FEV1 response (at least 1.15 times the corresponding test-day baseline value) during the 6-hour observation period at Day 57</description>
        <time_frame>During the 6-hour observation period after drug administration at Day 57</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Therapeutic FEV1 Response at Day 57</title>
          <description>The time interval between the onset and the the termination of a therapeutic FEV1 response (at least 1.15 times the corresponding test-day baseline value) during the 6-hour observation period at Day 57</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165" lower_limit="0" upper_limit="288"/>
                    <measurement group_id="O2" value="194" lower_limit="11" upper_limit="318"/>
                    <measurement group_id="O3" value="84" lower_limit="0" upper_limit="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Therapeutic FEV1 Response at Day 85</title>
        <description>The time interval between the onset and the the termination of a therapeutic FEV1 response (at least 1.15 times the corresponding test-day baseline value) during the 6-hour observation period at Day 85</description>
        <time_frame>During the 6-hour observation period after drug administration at Day 85</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Therapeutic FEV1 Response at Day 85</title>
          <description>The time interval between the onset and the the termination of a therapeutic FEV1 response (at least 1.15 times the corresponding test-day baseline value) during the 6-hour observation period at Day 85</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168" lower_limit="1" upper_limit="284"/>
                    <measurement group_id="O2" value="172" lower_limit="0" upper_limit="302"/>
                    <measurement group_id="O3" value="70" lower_limit="0" upper_limit="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Peak FEV1 Response at Day 1</title>
        <description>The first time point at which the maximum change in recorded FEV1 data from the corresponding test-day baseline occurred during the 6-hours observation period after drug administration at Day 1</description>
        <time_frame>Within the 6-hour post-treatment observation period at Day 1</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Peak FEV1 Response at Day 1</title>
          <description>The first time point at which the maximum change in recorded FEV1 data from the corresponding test-day baseline occurred during the 6-hours observation period after drug administration at Day 1</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="30" upper_limit="120"/>
                    <measurement group_id="O2" value="60" lower_limit="60" upper_limit="120"/>
                    <measurement group_id="O3" value="120" lower_limit="60" upper_limit="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Peak FEV1 Response at Day 29</title>
        <description>The first time point at which the maximum change in recorded FEV1 data from the corresponding test-day baseline occurred during the 6-hours observation period after drug administration at Day 29</description>
        <time_frame>Within the 6-hour post-treatment observation period at Day 29</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Peak FEV1 Response at Day 29</title>
          <description>The first time point at which the maximum change in recorded FEV1 data from the corresponding test-day baseline occurred during the 6-hours observation period after drug administration at Day 29</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="30" upper_limit="120"/>
                    <measurement group_id="O2" value="60" lower_limit="30" upper_limit="120"/>
                    <measurement group_id="O3" value="120" lower_limit="45" upper_limit="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Peak FEV1 Response at Day 57</title>
        <description>The first time point at which the maximum change in recorded FEV1 data from the corresponding test-day baseline occurred during the 6-hours observation period after drug administration at Day 57</description>
        <time_frame>Within the 6-hour post-treatment observation period at Day 57</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Peak FEV1 Response at Day 57</title>
          <description>The first time point at which the maximum change in recorded FEV1 data from the corresponding test-day baseline occurred during the 6-hours observation period after drug administration at Day 57</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="30" upper_limit="120"/>
                    <measurement group_id="O2" value="60" lower_limit="30" upper_limit="120"/>
                    <measurement group_id="O3" value="60" lower_limit="30" upper_limit="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Peak FEV1 Response at Day 85</title>
        <description>The first time point at which the maximum change in recorded FEV1 data from the corresponding test-day baseline occurred during the 6-hours observation period after drug administration at Day 85</description>
        <time_frame>Within the 6-hour post-treatment observation period at Day 85</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Peak FEV1 Response at Day 85</title>
          <description>The first time point at which the maximum change in recorded FEV1 data from the corresponding test-day baseline occurred during the 6-hours observation period after drug administration at Day 85</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="30" upper_limit="120"/>
                    <measurement group_id="O2" value="60" lower_limit="30" upper_limit="120"/>
                    <measurement group_id="O3" value="60" lower_limit="30" upper_limit="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC AUC0-6 at Day 1</title>
        <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 1</description>
        <time_frame>Before drug administration to 6 hours after drug administration at Day 1</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FVC AUC0-6 at Day 1</title>
          <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 1</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.337" spread="0.015"/>
                    <measurement group_id="O2" value="0.354" spread="0.015"/>
                    <measurement group_id="O3" value="0.25" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established.</non_inferiority_desc>
            <p_value>0.417</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.017</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.058</ci_lower_limit>
            <ci_upper_limit>0.024</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC AUC0-6 at Day 29</title>
        <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 29</description>
        <time_frame>Before drug administration to 6 hours after drug administration at Day 29</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FVC AUC0-6 at Day 29</title>
          <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 29</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.015"/>
                    <measurement group_id="O2" value="0.319" spread="0.015"/>
                    <measurement group_id="O3" value="0.246" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established.</non_inferiority_desc>
            <p_value>0.3505</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.019</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.059</ci_lower_limit>
            <ci_upper_limit>0.021</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC AUC0-6 at Day 57</title>
        <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 57</description>
        <time_frame>Before drug administration to 6 hours after drug administration on Day 57</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FVC AUC0-6 at Day 57</title>
          <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 57</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.284" spread="0.015"/>
                    <measurement group_id="O2" value="0.303" spread="0.015"/>
                    <measurement group_id="O3" value="0.22" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established.</non_inferiority_desc>
            <p_value>0.3499</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.019</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.058</ci_lower_limit>
            <ci_upper_limit>0.021</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC AUC0-6 at Day 85</title>
        <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 85</description>
        <time_frame>Before drug administration to 6 hours after drug administration on Day 85</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FVC AUC0-6 at Day 85</title>
          <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 85</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.279" spread="0.015"/>
                    <measurement group_id="O2" value="0.283" spread="0.015"/>
                    <measurement group_id="O3" value="0.219" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established.</non_inferiority_desc>
            <p_value>0.8288</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.004</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.044</ci_lower_limit>
            <ci_upper_limit>0.035</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC AUC0-4 at Day 1</title>
        <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 1</description>
        <time_frame>Before drug administration to 4 hours after drug administration on Day 1</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FVC AUC0-4 at Day 1</title>
          <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 1</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.408" spread="0.016"/>
                    <measurement group_id="O2" value="0.422" spread="0.016"/>
                    <measurement group_id="O3" value="0.297" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is purely exploratory.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.112</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.069</ci_lower_limit>
            <ci_upper_limit>0.154</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC AUC0-4 at Day 29</title>
        <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 29</description>
        <time_frame>Before drug administration to 4 hours after drug administration on Day 29</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FVC AUC0-4 at Day 29</title>
          <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 29</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.381" spread="0.015"/>
                    <measurement group_id="O2" value="0.388" spread="0.015"/>
                    <measurement group_id="O3" value="0.291" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is purely exploratory.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.049</ci_lower_limit>
            <ci_upper_limit>0.132</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC AUC0-4 at Day 57</title>
        <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 57</description>
        <time_frame>Before drug administration to 4 hours after drug administration on Day 57</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FVC AUC0-4 at Day 57</title>
          <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 57</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.361" spread="0.015"/>
                    <measurement group_id="O2" value="0.380" spread="0.015"/>
                    <measurement group_id="O3" value="0.264" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is purely exploratory.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.097</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.056</ci_lower_limit>
            <ci_upper_limit>0.138</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC AUC0-4 at Day 85</title>
        <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 85</description>
        <time_frame>Before drug administration to 4 hours after drug administration on Day 85</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FVC AUC0-4 at Day 85</title>
          <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 85</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.359" spread="0.015"/>
                    <measurement group_id="O2" value="0.359" spread="0.015"/>
                    <measurement group_id="O3" value="0.265" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is purely exploratory.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.094</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.054</ci_lower_limit>
            <ci_upper_limit>0.135</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC AUC4-6 at Day 1</title>
        <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 1</description>
        <time_frame>Between 4 hours and 6 hours after drug administration on Day 1</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data 4-6 hours</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FVC AUC4-6 at Day 1</title>
          <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 1</description>
          <population>Full Analysis Set for Pulmonary Function Test Data 4-6 hours</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="447"/>
                <count group_id="O2" value="449"/>
                <count group_id="O3" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.017"/>
                    <measurement group_id="O2" value="0.221" spread="0.017"/>
                    <measurement group_id="O3" value="0.156" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established.</non_inferiority_desc>
            <p_value>0.0688</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.043</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.003</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC AUC4-6 at Day 29</title>
        <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 29</description>
        <time_frame>Between 4 hours and 6 hours after drug administration on Day 29</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data 4-6 hours</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FVC AUC4-6 at Day 29</title>
          <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 29</description>
          <population>Full Analysis Set for Pulmonary Function Test Data 4-6 hours</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="447"/>
                <count group_id="O2" value="449"/>
                <count group_id="O3" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.137" spread="0.017"/>
                    <measurement group_id="O2" value="0.180" spread="0.017"/>
                    <measurement group_id="O3" value="0.156" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established.</non_inferiority_desc>
            <p_value>0.3895</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.064</ci_lower_limit>
            <ci_upper_limit>0.025</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC AUC4-6 at Day 57</title>
        <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 57</description>
        <time_frame>Between 4 hours and 6 hours after drug administration on Day 57</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data 4-6 hours</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FVC AUC4-6 at Day 57</title>
          <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 57</description>
          <population>Full Analysis Set for Pulmonary Function Test Data 4-6 hours</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="447"/>
                <count group_id="O2" value="449"/>
                <count group_id="O3" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.128" spread="0.016"/>
                    <measurement group_id="O2" value="0.147" spread="0.016"/>
                    <measurement group_id="O3" value="0.13" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established.</non_inferiority_desc>
            <p_value>0.959</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.001</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.045</ci_lower_limit>
            <ci_upper_limit>0.042</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC AUC4-6 at Day 85</title>
        <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 85</description>
        <time_frame>Between 4 hours and 6 hours after drug administration on Day 85</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data 4-6 hours</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FVC AUC4-6 at Day 85</title>
          <description>Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 85</description>
          <population>Full Analysis Set for Pulmonary Function Test Data 4-6 hours</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="447"/>
                <count group_id="O2" value="449"/>
                <count group_id="O3" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.117" spread="0.017"/>
                    <measurement group_id="O2" value="0.130" spread="0.017"/>
                    <measurement group_id="O3" value="0.124" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established.</non_inferiority_desc>
            <p_value>0.7652</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.007</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.053</ci_lower_limit>
            <ci_upper_limit>0.039</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FVC Response at Day 1</title>
        <description>Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 1</description>
        <time_frame>Within the first 2-hour post-treatment interval at Day 1</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FVC Response at Day 1</title>
          <description>Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 1</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.017"/>
                    <measurement group_id="O2" value="0.612" spread="0.017"/>
                    <measurement group_id="O3" value="0.479" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established.</non_inferiority_desc>
            <p_value>0.6244</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.011</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.057</ci_lower_limit>
            <ci_upper_limit>0.034</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FVC Response at Day 29</title>
        <description>Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 29</description>
        <time_frame>Within the first 2-hour post-treatment interval at Day 29</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FVC Response at Day 29</title>
          <description>Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 29</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.594" spread="0.017"/>
                    <measurement group_id="O2" value="0.591" spread="0.017"/>
                    <measurement group_id="O3" value="0.465" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established.</non_inferiority_desc>
            <p_value>0.873</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.004</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.041</ci_lower_limit>
            <ci_upper_limit>0.049</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FVC Response at Day 57</title>
        <description>Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 57</description>
        <time_frame>Within the first 2-hour post-treatment interval at Day 57</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FVC Response at Day 57</title>
          <description>Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 57</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.562" spread="0.017"/>
                    <measurement group_id="O2" value="0.577" spread="0.017"/>
                    <measurement group_id="O3" value="0.445" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established.</non_inferiority_desc>
            <p_value>0.5294</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.015</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.06</ci_lower_limit>
            <ci_upper_limit>0.031</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FVC Response at Day 85</title>
        <description>Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 85</description>
        <time_frame>Within the first 2-hour post-treatment interval at Day 85</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FVC Response at Day 85</title>
          <description>Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 85</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.575" spread="0.017"/>
                    <measurement group_id="O2" value="0.562" spread="0.017"/>
                    <measurement group_id="O3" value="0.449" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established.</non_inferiority_desc>
            <p_value>0.563</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.013</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.032</ci_lower_limit>
            <ci_upper_limit>0.058</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FVC Response at Day 1</title>
        <description>Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 1</description>
        <time_frame>Within the first 2-hour post-treatment interval at Day 1</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FVC Response at Day 1</title>
          <description>Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 1</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.017"/>
                    <measurement group_id="O2" value="0.612" spread="0.017"/>
                    <measurement group_id="O3" value="0.479" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is purely exploratory.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.121</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.075</ci_lower_limit>
            <ci_upper_limit>0.167</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FVC Response at Day 29</title>
        <description>Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 29</description>
        <time_frame>Within the first 2-hour post-treatment interval at Day 29</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FVC Response at Day 29</title>
          <description>Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 29</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.594" spread="0.017"/>
                    <measurement group_id="O2" value="0.591" spread="0.017"/>
                    <measurement group_id="O3" value="0.465" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is purely exploratory.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.129</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.084</ci_lower_limit>
            <ci_upper_limit>0.174</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FVC Response at Day 57</title>
        <description>Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 57</description>
        <time_frame>Within the first 2-hour post-treatment interval at Day 57</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FVC Response at Day 57</title>
          <description>Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 57</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.562" spread="0.017"/>
                    <measurement group_id="O2" value="0.577" spread="0.017"/>
                    <measurement group_id="O3" value="0.445" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is purely exploratory.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.118</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.072</ci_lower_limit>
            <ci_upper_limit>0.163</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FVC Response at Day 85</title>
        <description>Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 85</description>
        <time_frame>Within the first 2-hour post-treatment interval at Day 85</time_frame>
        <population>Full Analysis Set for Pulmonary Function Test Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FVC Response at Day 85</title>
          <description>Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 85</description>
          <population>Full Analysis Set for Pulmonary Function Test Data</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.575" spread="0.017"/>
                    <measurement group_id="O2" value="0.562" spread="0.017"/>
                    <measurement group_id="O3" value="0.449" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is purely exploratory.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.126</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.081</ci_lower_limit>
            <ci_upper_limit>0.171</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rescue Medication Use on Pulmonary Test Day 1</title>
        <description>Number of patients used rescue medication during the 6-hour pulmonary function testing after drug administration on Day 1</description>
        <time_frame>During the 6-hour pulmonary function testing after drug administration on Day 1</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Rescue Medication Use on Pulmonary Test Day 1</title>
          <description>Number of patients used rescue medication during the 6-hour pulmonary function testing after drug administration on Day 1</description>
          <population>Treated Set</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="486"/>
                <count group_id="O2" value="491"/>
                <count group_id="O3" value="483"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rescue Medication Use on Pulmonary Test Day 29</title>
        <description>Number of patients used rescue medication during the 6-hour pulmonary function testing after drug administration on Day 29</description>
        <time_frame>During the 6-hour pulmonary function testing after drug administration on Day 29</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Rescue Medication Use on Pulmonary Test Day 29</title>
          <description>Number of patients used rescue medication during the 6-hour pulmonary function testing after drug administration on Day 29</description>
          <population>Treated Set</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="486"/>
                <count group_id="O2" value="491"/>
                <count group_id="O3" value="483"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rescue Medication Use on Pulmonary Test Day 57</title>
        <description>Number of patients used rescue medication during the 6-hour pulmonary function testing after drug administration on Day 57</description>
        <time_frame>During the 6-hour pulmonary function testing after drug administration on Day 57</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Rescue Medication Use on Pulmonary Test Day 57</title>
          <description>Number of patients used rescue medication during the 6-hour pulmonary function testing after drug administration on Day 57</description>
          <population>Treated Set</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="486"/>
                <count group_id="O2" value="491"/>
                <count group_id="O3" value="483"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rescue Medication Use on Pulmonary Test Day 85</title>
        <description>Number of patients used rescue medication during the 6-hour pulmonary function testing after drug administration on Day 85</description>
        <time_frame>During the 6-hour pulmonary function testing after drug administration on Day 85</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Rescue Medication Use on Pulmonary Test Day 85</title>
          <description>Number of patients used rescue medication during the 6-hour pulmonary function testing after drug administration on Day 85</description>
          <population>Treated Set</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="486"/>
                <count group_id="O2" value="491"/>
                <count group_id="O3" value="483"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Night-time Rescue Medication Use</title>
        <description>The mean number of puffs of rescue medication used during the night-time per week during the entire study (including baseline and on-treatment period)</description>
        <time_frame>During the 2-week baseline washout period and the 12-week treatment period</time_frame>
        <population>Full Analysis Set for Diary Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Night-time Rescue Medication Use</title>
          <description>The mean number of puffs of rescue medication used during the night-time per week during the entire study (including baseline and on-treatment period)</description>
          <population>Full Analysis Set for Diary Data</population>
          <units>puffs</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="471"/>
                <count group_id="O2" value="467"/>
                <count group_id="O3" value="454"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.977" spread="0.047"/>
                    <measurement group_id="O2" value="0.977" spread="0.047"/>
                    <measurement group_id="O3" value="0.997" spread="0.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established.</non_inferiority_desc>
            <p_value>0.9943</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.00045</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06396</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.1259</ci_lower_limit>
            <ci_upper_limit>0.125</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is purely exploratory.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7569</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.01995</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06441</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1463</ci_lower_limit>
            <ci_upper_limit>0.1064</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daytime Rescue Medication Use</title>
        <description>The mean number of puffs of rescue medication used during the daytime per week during the entire study (including baseline and on-treatment period)</description>
        <time_frame>During the 2-week baseline washout period and the 12-week treatment period</time_frame>
        <population>Full Analysis Set for Diary Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Daytime Rescue Medication Use</title>
          <description>The mean number of puffs of rescue medication used during the daytime per week during the entire study (including baseline and on-treatment period)</description>
          <population>Full Analysis Set for Diary Data</population>
          <units>puffs</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="453"/>
                <count group_id="O2" value="458"/>
                <count group_id="O3" value="438"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.089"/>
                    <measurement group_id="O2" value="2.191" spread="0.089"/>
                    <measurement group_id="O3" value="2.456" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established.</non_inferiority_desc>
            <p_value>0.3659</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1091</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1206</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.1276</ci_lower_limit>
            <ci_upper_limit>0.3458</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is purely exploratory.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.203</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1554</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.122</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3947</ci_lower_limit>
            <ci_upper_limit>0.08395</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Night-time Symptom Score</title>
        <description>The weekly mean night-time symptom score per week during the entire study (including baseline and on-treatment period).
Night−time COPD symptoms: 0=none 1=some − slept well 2=woke once 3=woke several times 4=woke most of night</description>
        <time_frame>During the 2-week baseline washout period and the 12-week treatment period</time_frame>
        <population>Full Analysis Set for Diary Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Night-time Symptom Score</title>
          <description>The weekly mean night-time symptom score per week during the entire study (including baseline and on-treatment period).
Night−time COPD symptoms: 0=none 1=some − slept well 2=woke once 3=woke several times 4=woke most of night</description>
          <population>Full Analysis Set for Diary Data</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="471"/>
                <count group_id="O2" value="467"/>
                <count group_id="O3" value="454"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.922" spread="0.023"/>
                    <measurement group_id="O2" value="0.914" spread="0.024"/>
                    <measurement group_id="O3" value="0.857" spread="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established.</non_inferiority_desc>
            <p_value>0.809</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.007734</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03199</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.05503</ci_lower_limit>
            <ci_upper_limit>0.0705</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is purely exploratory.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.044</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.06501</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03225</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.001746</ci_lower_limit>
            <ci_upper_limit>0.1283</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daytime Symptom Score</title>
        <description>The weekly mean daytime symptom score per week during the entire study (including baseline and on-treatment period).
Daytime COPD symptoms: 0=none 1=occasional 2=frequent, no interference with activities 3=most of day, interference with activities 4=prevent working and activities</description>
        <time_frame>During the 2-week baseline washout period and the 12-week treatment period</time_frame>
        <population>Full Analysis Set for Diary Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Daytime Symptom Score</title>
          <description>The weekly mean daytime symptom score per week during the entire study (including baseline and on-treatment period).
Daytime COPD symptoms: 0=none 1=occasional 2=frequent, no interference with activities 3=most of day, interference with activities 4=prevent working and activities</description>
          <population>Full Analysis Set for Diary Data</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="452"/>
                <count group_id="O2" value="456"/>
                <count group_id="O3" value="437"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.015" spread="0.022"/>
                    <measurement group_id="O2" value="1.002" spread="0.022"/>
                    <measurement group_id="O3" value="0.999" spread="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established.</non_inferiority_desc>
            <p_value>0.6674</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0129</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03002</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.04598</ci_lower_limit>
            <ci_upper_limit>0.07179</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is purely exploratory.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.604</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.01573</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03033</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.04376</ci_lower_limit>
            <ci_upper_limit>0.07523</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Peak Expiratory Flow Rate (PEFR)</title>
        <description>The weekly mean trough PEFR during the entire study (including baseline and on-treatment period)</description>
        <time_frame>During the 2-week baseline washout period and the 12-week treatment period and PEFR taken before administration of study medication</time_frame>
        <population>Full Analysis Set for Diary Data</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Peak Expiratory Flow Rate (PEFR)</title>
          <description>The weekly mean trough PEFR during the entire study (including baseline and on-treatment period)</description>
          <population>Full Analysis Set for Diary Data</population>
          <units>liters/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="441"/>
                <count group_id="O2" value="444"/>
                <count group_id="O3" value="426"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191.95" spread="1.51"/>
                    <measurement group_id="O2" value="190.290" spread="1.526"/>
                    <measurement group_id="O3" value="189.51" spread="1.551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established.</non_inferiority_desc>
            <p_value>0.4238</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.6526</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.0653</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.3995</ci_lower_limit>
            <ci_upper_limit>5.7047</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is purely exploratory.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2431</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.4376</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.0874</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6578</ci_lower_limit>
            <ci_upper_limit>6.533</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician's Global Evaluation Score on Pulmonary Function Testing Day 29</title>
        <description>Physician's Global Evaluation score is based on the need for concomitant medication, number and severity of exacerbations since the last visit, severity of cough, ability to exercise, amount of wheezing, etc.
Score: 1,2 = poor; 3,4 = fair; 5,6 =good; 7,8 = excellent.</description>
        <time_frame>Prior to pulmonary function test on Day 29</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Physician's Global Evaluation Score on Pulmonary Function Testing Day 29</title>
          <description>Physician's Global Evaluation score is based on the need for concomitant medication, number and severity of exacerbations since the last visit, severity of cough, ability to exercise, amount of wheezing, etc.
Score: 1,2 = poor; 3,4 = fair; 5,6 =good; 7,8 = excellent.</description>
          <population>Treated Set</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="480"/>
                <count group_id="O2" value="487"/>
                <count group_id="O3" value="481"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.936" spread="0.041"/>
                    <measurement group_id="O2" value="4.859" spread="0.041"/>
                    <measurement group_id="O3" value="4.99" spread="0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established.</non_inferiority_desc>
            <p_value>0.173</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.077</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.056</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.034</ci_lower_limit>
            <ci_upper_limit>0.187</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is purely exploratory.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.336</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.054</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.056</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.165</ci_lower_limit>
            <ci_upper_limit>0.056</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician's Global Evaluation Score on Pulmonary Function Testing Day 57</title>
        <description>Physician's Global Evaluation score is based on the need for concomitant medication, number and severity of exacerbations since the last visit, severity of cough, ability to exercise, amount of wheezing, etc.
Score: 1,2 = poor; 3,4 = fair; 5,6 =good; 7,8 = excellent.</description>
        <time_frame>Prior to pulmonary function test on Day 57</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Physician's Global Evaluation Score on Pulmonary Function Testing Day 57</title>
          <description>Physician's Global Evaluation score is based on the need for concomitant medication, number and severity of exacerbations since the last visit, severity of cough, ability to exercise, amount of wheezing, etc.
Score: 1,2 = poor; 3,4 = fair; 5,6 =good; 7,8 = excellent.</description>
          <population>Treated Set</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="480"/>
                <count group_id="O2" value="487"/>
                <count group_id="O3" value="481"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.971" spread="0.045"/>
                    <measurement group_id="O2" value="4.965" spread="0.045"/>
                    <measurement group_id="O3" value="5.04" spread="0.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established.</non_inferiority_desc>
            <p_value>0.924</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.006</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.062</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.115</ci_lower_limit>
            <ci_upper_limit>0.127</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is purely exploratory.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.266</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.069</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.062</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>0.053</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician's Global Evaluation Score on Pulmonary Function Testing Day 85</title>
        <description>Physician's Global Evaluation score is based on the need for concomitant medication, number and severity of exacerbations since the last visit, severity of cough, ability to exercise, amount of wheezing, etc.
Score: 1,2 = poor; 3,4 = fair; 5,6 =good; 7,8 = excellent.</description>
        <time_frame>Prior to pulmonary function test on Day 85</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Physician's Global Evaluation Score on Pulmonary Function Testing Day 85</title>
          <description>Physician's Global Evaluation score is based on the need for concomitant medication, number and severity of exacerbations since the last visit, severity of cough, ability to exercise, amount of wheezing, etc.
Score: 1,2 = poor; 3,4 = fair; 5,6 =good; 7,8 = excellent.</description>
          <population>Treated Set</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="480"/>
                <count group_id="O2" value="487"/>
                <count group_id="O3" value="481"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.115" spread="0.048"/>
                    <measurement group_id="O2" value="5.018" spread="0.048"/>
                    <measurement group_id="O3" value="5.097" spread="0.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This analysis is purely exploratory. Non-inferiority margin is not established.</non_inferiority_desc>
            <p_value>0.139</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.097</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.065</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.031</ci_lower_limit>
            <ci_upper_limit>0.225</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is purely exploratory.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.788</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.018</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.066</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.111</ci_lower_limit>
            <ci_upper_limit>0.146</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Chronic Obstructive Pulmonary Disease (COPD) Exacerbation During the On-treatment Period</title>
        <description>COPD exacerbation is defined as an increase or new onset of more than one of the following respiratory symptoms (cough, sputum, sputum purulence, wheezing, dyspnea, and chest tightness) having a duration of three or more days requiring treatment with an antibiotic and/or systemic steroids with or without hospital admission.</description>
        <time_frame>During the 12-week on-treatment period</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Chronic Obstructive Pulmonary Disease (COPD) Exacerbation During the On-treatment Period</title>
          <description>COPD exacerbation is defined as an increase or new onset of more than one of the following respiratory symptoms (cough, sputum, sputum purulence, wheezing, dyspnea, and chest tightness) having a duration of three or more days requiring treatment with an antibiotic and/or systemic steroids with or without hospital admission.</description>
          <population>Treated Set</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="486"/>
                <count group_id="O2" value="491"/>
                <count group_id="O3" value="483"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.81"/>
                    <measurement group_id="O2" value="13.03"/>
                    <measurement group_id="O3" value="10.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>COPD Exacerbation Rate During the On-treatment Period</title>
        <description>Proportion of patients experiencing a COPD exacerbation per patient year. COPD exacerbation is defined as an increase or new onset of more than one of the following respiratory symptoms (cough, sputum, sputum purulence, wheezing, dyspnea, and chest tightness) having a duration of three or more days requiring treatment with an antibiotic and/or systemic steroids with or without hospital admission.</description>
        <time_frame>During the 12-week on-treatment period</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>COPD Exacerbation Rate During the On-treatment Period</title>
          <description>Proportion of patients experiencing a COPD exacerbation per patient year. COPD exacerbation is defined as an increase or new onset of more than one of the following respiratory symptoms (cough, sputum, sputum purulence, wheezing, dyspnea, and chest tightness) having a duration of three or more days requiring treatment with an antibiotic and/or systemic steroids with or without hospital admission.</description>
          <population>Treated Set</population>
          <units>Proportion of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="486"/>
                <count group_id="O2" value="491"/>
                <count group_id="O3" value="483"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76"/>
                    <measurement group_id="O2" value="0.69"/>
                    <measurement group_id="O3" value="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>COPD Exacerbation During the On-treatment Period</title>
        <description>COPD exacerbation is defined as an increase or new onset of more than one of the following respiratory symptoms (cough, sputum, sputum purulence, wheezing, dyspnea, and chest tightness) having a duration of three or more days requiring treatment with an antibiotic and/or systemic steroids with or without hospital admission.</description>
        <time_frame>During the 12-week on-treatment period</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>COPD Exacerbation During the On-treatment Period</title>
          <description>COPD exacerbation is defined as an increase or new onset of more than one of the following respiratory symptoms (cough, sputum, sputum purulence, wheezing, dyspnea, and chest tightness) having a duration of three or more days requiring treatment with an antibiotic and/or systemic steroids with or without hospital admission.</description>
          <population>Treated Set</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="486"/>
                <count group_id="O2" value="491"/>
                <count group_id="O3" value="483"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.27"/>
                    <measurement group_id="O2" value="2.93"/>
                    <measurement group_id="O3" value="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency Distribution of Satisfaction Rating With Inhaler Attributes</title>
        <time_frame>12 weeks</time_frame>
        <population>Treated set (US patients)</population>
        <group_list>
          <group group_id="O1">
            <title>MDI Device</title>
            <description>MDI Inhalers</description>
          </group>
          <group group_id="O2">
            <title>RESPIMAT Device</title>
            <description>Respimat Inhalers</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency Distribution of Satisfaction Rating With Inhaler Attributes</title>
          <population>Treated set (US patients)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="834"/>
                <count group_id="O2" value="835"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfied/dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="351"/>
                    <measurement group_id="O2" value="305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240"/>
                    <measurement group_id="O2" value="407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Rating Scores of Satisfaction With Inhaler - Overall Feeling of Inhaling Medicine</title>
        <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
        <time_frame>12 weeks</time_frame>
        <population>Treated set (US patients)</population>
        <group_list>
          <group group_id="O1">
            <title>MDI Device</title>
            <description>MDI Inhalers</description>
          </group>
          <group group_id="O2">
            <title>RESPIMAT Device</title>
            <description>Respimat Inhalers</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Rating Scores of Satisfaction With Inhaler - Overall Feeling of Inhaling Medicine</title>
          <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
          <population>Treated set (US patients)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="834"/>
                <count group_id="O2" value="835"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.411" spread="0.049"/>
                    <measurement group_id="O2" value="5.810" spread="0.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference: Respimat − MDI</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.398</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.065</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Rating Scores of Satisfaction With Inhaler - Feeling That the Inhaled Dose Goes to the Lung</title>
        <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
        <time_frame>12 weeks</time_frame>
        <population>Treated set (US patients)</population>
        <group_list>
          <group group_id="O1">
            <title>MDI Device</title>
            <description>MDI Inhalers</description>
          </group>
          <group group_id="O2">
            <title>RESPIMAT Device</title>
            <description>Respimat Inhalers</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Rating Scores of Satisfaction With Inhaler - Feeling That the Inhaled Dose Goes to the Lung</title>
          <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
          <population>Treated set (US patients)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="833"/>
                <count group_id="O2" value="835"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.326" spread="0.049"/>
                    <measurement group_id="O2" value="5.808" spread="0.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference: Respimat − MDI</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.482</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.065</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Rating Scores of Satisfaction With Inhaler - Telling the Amount of Medication Left</title>
        <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
        <time_frame>12 weeks</time_frame>
        <population>Treated set (US patients)</population>
        <group_list>
          <group group_id="O1">
            <title>MDI Device</title>
            <description>MDI Inhalers</description>
          </group>
          <group group_id="O2">
            <title>RESPIMAT Device</title>
            <description>Respimat Inhalers</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Rating Scores of Satisfaction With Inhaler - Telling the Amount of Medication Left</title>
          <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
          <population>Treated set (US patients)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="833"/>
                <count group_id="O2" value="835"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.573" spread="0.057"/>
                    <measurement group_id="O2" value="6.184" spread="0.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference: Respimat − MDI</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.612</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.075</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Rating Scores of Satisfaction With Inhaler - The Inhaler Works Reliably</title>
        <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
        <time_frame>12 weeks</time_frame>
        <population>Treated set (US patients)</population>
        <group_list>
          <group group_id="O1">
            <title>MDI Device</title>
            <description>MDI Inhalers</description>
          </group>
          <group group_id="O2">
            <title>RESPIMAT Device</title>
            <description>Respimat Inhalers</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Rating Scores of Satisfaction With Inhaler - The Inhaler Works Reliably</title>
          <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
          <population>Treated set (US patients)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="834"/>
                <count group_id="O2" value="835"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.682" spread="0.044"/>
                    <measurement group_id="O2" value="6.190" spread="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference: Respimat − MDI</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.508</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.058</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Rating Scores of Satisfaction With Inhaler - Ease of Inhaling a Dose From the Inhaler</title>
        <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
        <time_frame>12 weeks</time_frame>
        <population>Treated set (US patients)</population>
        <group_list>
          <group group_id="O1">
            <title>MDI Device</title>
            <description>MDI Inhalers</description>
          </group>
          <group group_id="O2">
            <title>RESPIMAT Device</title>
            <description>Respimat Inhalers</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Rating Scores of Satisfaction With Inhaler - Ease of Inhaling a Dose From the Inhaler</title>
          <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
          <population>Treated set (US patients)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="834"/>
                <count group_id="O2" value="835"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.729" spread="0.046"/>
                    <measurement group_id="O2" value="6.150" spread="0.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference: Respimat − MDI</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.421</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.061</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Rating Scores of Satisfaction With Inhaler - Instructions for Use</title>
        <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
        <time_frame>12 weeks</time_frame>
        <population>Treated set (US patients)</population>
        <group_list>
          <group group_id="O1">
            <title>MDI Device</title>
            <description>MDI Inhalers</description>
          </group>
          <group group_id="O2">
            <title>RESPIMAT Device</title>
            <description>Respimat Inhalers</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Rating Scores of Satisfaction With Inhaler - Instructions for Use</title>
          <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
          <population>Treated set (US patients)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="834"/>
                <count group_id="O2" value="834"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.048" spread="0.036"/>
                    <measurement group_id="O2" value="6.275" spread="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference: Respimat − MDI</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.226</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.047</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Rating Scores of Satisfaction With Inhaler - The Inhaler is Durable</title>
        <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
        <time_frame>12 weeks</time_frame>
        <population>Treated set (US patients)</population>
        <group_list>
          <group group_id="O1">
            <title>MDI Device</title>
            <description>MDI Inhalers</description>
          </group>
          <group group_id="O2">
            <title>RESPIMAT Device</title>
            <description>Respimat Inhalers</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Rating Scores of Satisfaction With Inhaler - The Inhaler is Durable</title>
          <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
          <population>Treated set (US patients)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="834"/>
                <count group_id="O2" value="835"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.014" spread="0.037"/>
                    <measurement group_id="O2" value="6.279" spread="0.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference: Respimat − MDI</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.265</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.050</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Rating Scores of Satisfaction With Inhaler - Using the Inhaler</title>
        <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
        <time_frame>12 weeks</time_frame>
        <population>Treated set (US patients)</population>
        <group_list>
          <group group_id="O1">
            <title>MDI Device</title>
            <description>MDI Inhalers</description>
          </group>
          <group group_id="O2">
            <title>RESPIMAT Device</title>
            <description>Respimat Inhalers</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Rating Scores of Satisfaction With Inhaler - Using the Inhaler</title>
          <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
          <population>Treated set (US patients)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="833"/>
                <count group_id="O2" value="835"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.749" spread="0.045"/>
                    <measurement group_id="O2" value="6.127" spread="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference: Respimat − MDI</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.378</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.060</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Rating Scores of Satisfaction With Inhaler - Speed of Medicine Coming Out of the Inhaler</title>
        <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
        <time_frame>12 weeks</time_frame>
        <population>Treated set (US patients)</population>
        <group_list>
          <group group_id="O1">
            <title>MDI Device</title>
            <description>MDI Inhalers</description>
          </group>
          <group group_id="O2">
            <title>RESPIMAT Device</title>
            <description>Respimat Inhalers</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Rating Scores of Satisfaction With Inhaler - Speed of Medicine Coming Out of the Inhaler</title>
          <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
          <population>Treated set (US patients)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="834"/>
                <count group_id="O2" value="835"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.715" spread="0.047"/>
                    <measurement group_id="O2" value="6.117" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference: Respimat − MDI</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.402</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.062</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Rating Scores of Satisfaction With Inhaler - Overall Satisfaction With Inhaler</title>
        <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
        <time_frame>12 weeks</time_frame>
        <population>Treated set (US patients)</population>
        <group_list>
          <group group_id="O1">
            <title>MDI Device</title>
            <description>MDI Inhalers</description>
          </group>
          <group group_id="O2">
            <title>RESPIMAT Device</title>
            <description>Respimat Inhalers</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Rating Scores of Satisfaction With Inhaler - Overall Satisfaction With Inhaler</title>
          <description>Patients rated their response on a seven point Likert scale:
1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.</description>
          <population>Treated set (US patients)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="834"/>
                <count group_id="O2" value="835"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.639" spread="0.048"/>
                    <measurement group_id="O2" value="6.103" spread="0.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference: Respimat − MDI</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.464</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.063</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device Preference (Respimat or MDI)</title>
        <description>Frequency of patients due to device preference</description>
        <time_frame>12 weeks</time_frame>
        <population>Treated set (US patients)</population>
        <group_list>
          <group group_id="O1">
            <title>Number of Patients</title>
            <description>Total number of patients due to device preference</description>
          </group>
        </group_list>
        <measure>
          <title>Device Preference (Respimat or MDI)</title>
          <description>Frequency of patients due to device preference</description>
          <population>Treated set (US patients)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="835"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Prefer Respimat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prefer MDI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No preference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rating of Action of Turning Clear Base of Respimat</title>
        <description>Frequency of patients due to rating of action of turning clear base of Respimat</description>
        <time_frame>12 weeks</time_frame>
        <population>Treated set (US patients)</population>
        <group_list>
          <group group_id="O1">
            <title>Number of Patients</title>
            <description>Total number of patients due to rating of turning</description>
          </group>
        </group_list>
        <measure>
          <title>Rating of Action of Turning Clear Base of Respimat</title>
          <description>Frequency of patients due to rating of action of turning clear base of Respimat</description>
          <population>Treated set (US patients)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="835"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very easy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Easy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither easy nor difficult</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difficult</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very difficult</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Noncompartmental Pharmacokinetic Parameters of Ipratropium at Steady State</title>
        <description>Geometric mean area under the plasma drug concentration time curve over one dosing interval (AUCτ). Each patient had eight plasma samples (trough pre-dose, 5, 15, 30, and 60 minutes post-dose, as well as 2, 4, and 6 hours post-dose).</description>
        <time_frame>Before drug administration to 6 hours after drug administration on Day 29</time_frame>
        <population>All patients in FAS who were from U.S. study sites and whose blood and/or urine samples were collected at Visit 3 according to the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Noncompartmental Pharmacokinetic Parameters of Ipratropium at Steady State</title>
          <description>Geometric mean area under the plasma drug concentration time curve over one dosing interval (AUCτ). Each patient had eight plasma samples (trough pre-dose, 5, 15, 30, and 60 minutes post-dose, as well as 2, 4, and 6 hours post-dose).</description>
          <population>All patients in FAS who were from U.S. study sites and whose blood and/or urine samples were collected at Visit 3 according to the protocol.</population>
          <units>pg*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128" spread="55.4"/>
                    <measurement group_id="O2" value="123" spread="79.3"/>
                    <measurement group_id="O3" value="115" spread="50.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Noncompartmental Parameters of Albuterol at Steady State</title>
        <description>Geometric mean area under the plasma drug concentration time curve over one dosing interval (AUCτ). Each patient had eight plasma samples (trough pre-dose, 5, 15, 30, and 60 minutes post-dose, as well as 2, 4, and 6 hours post-dose).</description>
        <time_frame>Before drug administration to 6 hours after drug administration on Day 29</time_frame>
        <population>All patients in FAS who were from U.S. study sites and whose blood and/or urine samples were collected at Visit 3 according to the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
        </group_list>
        <measure>
          <title>Noncompartmental Parameters of Albuterol at Steady State</title>
          <description>Geometric mean area under the plasma drug concentration time curve over one dosing interval (AUCτ). Each patient had eight plasma samples (trough pre-dose, 5, 15, 30, and 60 minutes post-dose, as well as 2, 4, and 6 hours post-dose).</description>
          <population>All patients in FAS who were from U.S. study sites and whose blood and/or urine samples were collected at Visit 3 according to the protocol</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.09" spread="74.3"/>
                    <measurement group_id="O2" value="5.52" spread="61.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Amounts of Ipratropium [μg] Excreted in Urine for 0-2 Hours</title>
        <description>Cumulative amounts of Ipratropium [μg] excreted in urine - Planned time intervals 0-2, ss</description>
        <time_frame>Before drug administration to 2 hours after drug administration on Day 29</time_frame>
        <population>All patients in FAS who were from U.S. study sites and whose blood and/or urine samples were collected at Visit 3 according to the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 Mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Amounts of Ipratropium [μg] Excreted in Urine for 0-2 Hours</title>
          <description>Cumulative amounts of Ipratropium [μg] excreted in urine - Planned time intervals 0-2, ss</description>
          <population>All patients in FAS who were from U.S. study sites and whose blood and/or urine samples were collected at Visit 3 according to the protocol</population>
          <units>μg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.747" spread="148"/>
                    <measurement group_id="O2" value="0.692" spread="180"/>
                    <measurement group_id="O3" value="0.723" spread="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Amounts of Albuterol [μg] Excreted in Urine for 0-2 Hours</title>
        <description>Cumulative amounts of Albuterol [μg] excreted in urine - Planned time intervals 0−2,ss.</description>
        <time_frame>Before drug administration to 2 hours after drug administration on Day 29</time_frame>
        <population>All patients in FAS who were from U.S. study sites and whose blood and/or urine samples were collected at Visit 3 according to the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Amounts of Albuterol [μg] Excreted in Urine for 0-2 Hours</title>
          <description>Cumulative amounts of Albuterol [μg] excreted in urine - Planned time intervals 0−2,ss.</description>
          <population>All patients in FAS who were from U.S. study sites and whose blood and/or urine samples were collected at Visit 3 according to the protocol</population>
          <units>μg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" spread="143"/>
                    <measurement group_id="O2" value="20.3" spread="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Amounts of Ipratropium [μg] Excreted in Urine for 0-6 Hours</title>
        <description>Cumulative amounts of Ipratropium [μg] excreted in urine - Planned time intervals 0−6,ss</description>
        <time_frame>Before drug administration to 6 hours after drug administration on Day 26</time_frame>
        <population>All patients in FAS who were from U.S. study sites and whose blood and/or urine samples were collected at Visit 3 according to the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
          <group group_id="O3">
            <title>Ipratropium Respimat 20 mcg</title>
            <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Amounts of Ipratropium [μg] Excreted in Urine for 0-6 Hours</title>
          <description>Cumulative amounts of Ipratropium [μg] excreted in urine - Planned time intervals 0−6,ss</description>
          <population>All patients in FAS who were from U.S. study sites and whose blood and/or urine samples were collected at Visit 3 according to the protocol</population>
          <units>μg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66" spread="128"/>
                    <measurement group_id="O2" value="1.41" spread="143"/>
                    <measurement group_id="O3" value="1.51" spread="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Amounts of Albuterol [μg] Excreted in Urine for 0-6 Hours</title>
        <description>Cumulative amounts of Albuterol [μg] excreted in urine - Planned time intervals 0−6, ss</description>
        <time_frame>Before drug administration to 6 hours after drug administration on Day 29</time_frame>
        <population>All patients in FAS who were from U.S. study sites and whose blood and/or urine samples were collected at Visit 3 according to the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>COMBIVENT Respimat 20/100 mcg</title>
            <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
          </group>
          <group group_id="O2">
            <title>COMBIVENT CFC-MDI 36/206 mcg</title>
            <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Amounts of Albuterol [μg] Excreted in Urine for 0-6 Hours</title>
          <description>Cumulative amounts of Albuterol [μg] excreted in urine - Planned time intervals 0−6, ss</description>
          <population>All patients in FAS who were from U.S. study sites and whose blood and/or urine samples were collected at Visit 3 according to the protocol</population>
          <units>μg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7" spread="123"/>
                    <measurement group_id="O2" value="39.4" spread="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>COMBIVENT Respimat 20/100 mcg</title>
          <description>Combivent Respimat (20 mcg/100 mcg) plus placebo COMBIVENT MDI</description>
        </group>
        <group group_id="E2">
          <title>COMBIVENT CFC-MDI 36/206 mcg</title>
          <description>COMBIVENT MDI (36/206 mcg ) plus placebo Combivent Respimat</description>
        </group>
        <group group_id="E3">
          <title>Ipratropium Respimat 20 mcg</title>
          <description>Atrovent Respimat (20 mcg) plus placebo COMBIVENT MDI</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17"/>
                <counts group_id="E2" subjects_affected="33"/>
                <counts group_id="E3" subjects_affected="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Brain cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Small cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Angiopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61"/>
                <counts group_id="E2" subjects_affected="51"/>
                <counts group_id="E3" subjects_affected="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The FEV1 and FVC measurements at each observation time point were used to derive the primary and secondary efficacy endpoints and are not reported here. All statistical analyses for secondary endpoints are exploratory and the p-values are nominal.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Pharmaceuticals</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>800-542-6257 Option 4</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

